These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 14760171)

  • 61. Hippocrates revisited: the evidence for drug-eluting stents.
    Kereiakes DJ
    Circulation; 2003 Jun; 107(24):3012-4. PubMed ID: 12821588
    [No Abstract]   [Full Text] [Related]  

  • 62. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 63. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.
    Mehilli J; Dibra A; Kastrati A; Pache J; Dirschinger J; Schömig A;
    Eur Heart J; 2006 Feb; 27(3):260-6. PubMed ID: 16401670
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug-eluting stents and stent thrombosis: a cause for concern?
    Wernick MH; Jeremias A; Carrozza JP
    Coron Artery Dis; 2006 Dec; 17(8):661-5. PubMed ID: 17119373
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Classification and current treatment options of in-stent restenosis. Present status and future perspectives.
    Ong AT; Aoki J; McFadden EP; Serruys PW
    Herz; 2004 Mar; 29(2):187-94. PubMed ID: 15057440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drug-eluting stents: immediate and long-term results.
    Korovesis S; Karvouni E; Giazitzoglou E; Katritsis D
    Hellenic J Cardiol; 2005; 46(5):330-5. PubMed ID: 16295941
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries.
    Buszman P; Milewski K; Zurakowski A; Pajak J; Liszka Ł; Buszman P; Musioł E; AbuSamra M; Trznadel S; Kałuza G
    Kardiol Pol; 2010 May; 68(5):503-9. PubMed ID: 20491008
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis.
    Erglis A; Narbute I; Kumsars I; Jegere S; Mintale I; Zakke I; Strazdins U; Saltups A
    J Am Coll Cardiol; 2007 Aug; 50(6):491-7. PubMed ID: 17678730
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
    Stone GW; Ellis SG; Cannon L; Mann JT; Greenberg JD; Spriggs D; O'Shaughnessy CD; DeMaio S; Hall P; Popma JJ; Koglin J; Russell ME;
    JAMA; 2005 Sep; 294(10):1215-23. PubMed ID: 16160130
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.
    Sidhu S; Shafiq N; Malhotra S; Pandhi P; Grover A
    Br J Clin Pharmacol; 2006 Jun; 61(6):720-6. PubMed ID: 16722835
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.
    Degertekin M; Regar E; Tanabe K; Lee CH; Serruys PW
    Minerva Cardioangiol; 2002 Oct; 50(5):405-18. PubMed ID: 12384623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry.
    Fanggiday JC; Stella PR; Guyomi SH; Doevendans PA
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):629-35. PubMed ID: 18360855
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2015; 15(20):1-62. PubMed ID: 26719778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.